Literature DB >> 30421456

Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!

Lisa K Stamp1, Daniel F B Wright2, Nicola Dalbeth3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30421456      PMCID： PMC6533458          DOI： 10.1111/bcp.13798

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  15 in total

1.  Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!

Authors:  Lisa K Stamp; Daniel F B Wright; Nicola Dalbeth
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

2.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

3.  Relation between adverse events associated with allopurinol and renal function in patients with gout.

Authors:  J Vázquez-Mellado; E M Morales; C Pacheco-Tena; R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

4.  Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.

Authors:  Nicola Dalbeth; Sunil Kumar; Lisa Stamp; Peter Gow
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

5.  Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

Authors:  William B White; Kenneth G Saag; Michael A Becker; Jeffrey S Borer; Philip B Gorelick; Andrew Whelton; Barbara Hunt; Majin Castillo; Lhanoo Gunawardhana
Journal:  N Engl J Med       Date:  2018-03-12       Impact factor: 91.245

6.  Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Authors:  Lisa K Stamp; William J Taylor; Peter B Jones; Jo L Dockerty; Jill Drake; Christopher Frampton; Nicola Dalbeth
Journal:  Arthritis Rheum       Date:  2012-08

7.  An open-label, 6-month study of allopurinol safety in gout: The LASSO study.

Authors:  Michael A Becker; David Fitz-Patrick; Hyon K Choi; Nicola Dalbeth; Chris Storgard; Matt Cravets; Scott Baumgartner
Journal:  Semin Arthritis Rheum       Date:  2015-05-21       Impact factor: 5.532

8.  A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.

Authors:  Daniel Fb Wright; Matthew P Doogue; Murray L Barclay; Peter T Chapman; Nicholas B Cross; John H Irvine; Lisa K Stamp
Journal:  Eur J Clin Pharmacol       Date:  2016-09-28       Impact factor: 2.953

Review 9.  2016 updated EULAR evidence-based recommendations for the management of gout.

Authors:  P Richette; M Doherty; E Pascual; V Barskova; F Becce; J Castañeda-Sanabria; M Coyfish; S Guillo; T L Jansen; H Janssens; F Lioté; C Mallen; G Nuki; F Perez-Ruiz; J Pimentao; L Punzi; T Pywell; A So; A K Tausche; T Uhlig; J Zavada; W Zhang; F Tubach; T Bardin
Journal:  Ann Rheum Dis       Date:  2016-07-25       Impact factor: 19.103

10.  The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.

Authors:  Lisa K Stamp; Peter T Chapman; Murray Barclay; Anne Horne; Christopher Frampton; Paul Tan; Jill Drake; Nicola Dalbeth
Journal:  Arthritis Res Ther       Date:  2017-12-21       Impact factor: 5.156
View more
  3 in total

1.  Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.

Authors:  Solène M Laville; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

2.  Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!

Authors:  Lisa K Stamp; Daniel F B Wright; Nicola Dalbeth
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

3.  Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.

Authors:  Amayelle Rey; Benjamin Batteux; Solène M Laville; Justine Marienne; Kamel Masmoudi; Valérie Gras-Champel; Sophie Liabeuf
Journal:  Arthritis Res Ther       Date:  2019-11-08       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.